Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approvals for drug production and registration for the following four products from National Medical Products Administration of China (the "NMPA"), all being regarded as passing the consistency evaluation.

1. Potassium Chloride Injection (II) (100ml:1.5g): This product of the Group, being the second of such approvals for the PRC entities, is under type 3 chemical drug mainly used for the treatment of hypokalemia when oral potassium supplementation is not possible.

   This product further enriches the Group's portfolio of therapeutic infusion products, strengthening the Group's product layout and specialised clinical supply capability in intensive care unit (ICU) field.

2. Sodium Hyaluronate Eye Drops 0.3% (0.4ml:1.2mg): This product is under type 4 chemical drug mainly used for the treatment of corneal and conjunctival epithelial damage associated with the following conditions: endogenous conditions such as Sjögren's syndrome, Stevens-Johnson syndrome and dry eye syndrome, as well as endogenous conditions such as postoperative, drug-induced, traumatic and contact lens wear.

3. Sodium Hyaluronate Eye Drops 0.1% (0.4ml: 0.4mg): This product is under type 4 chemical drug mainly used for dry eye syndrome to relieve eye dryness symptoms.

   Both Sodium Hyaluronate Eye Drops abovementioned are in single-dose and preservative-free packaging. Together with previously approved Polyvinyl Alcohol Eye Drops, they form a product portfolio covering different degrees of dry eye syndrome, providing patients with tiered treatment options.

   The Group has a strategic layout in ophthalmic drug segment with single-dose and preservative-free formulations, and has built a product portfolio including anti-infectives, anti-allergens, intraocular pressure lowering, artificial tears and ocular anti-inflammatory, forming a dual-channel layout of in-hospital prescription drugs and retail OTC.

4. Metoclopramide Tablets (5mg): This product is under type 3 chemical drug mainly used for symptomatic treatment of nausea and vomiting caused by various diseases, short term treatment of symptomatic gastroesophageal reflux that is unresponsive to conventional treatment, and relief of symptoms of acute and recurrent diabetic gastroparesis. As stated in the Company's announcement dated 27 February 2026, the Group's Metoclopramide bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 6 August 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.